Personalized stem cell therapy is emerging as a promising new avenue of hope for people living with the long-term effects of Long COVID. The featured article highlights how regenerative medicine—especially mesenchymal stem cell (MSC)–based care—is shifting the focus from symptom suppression to true biological repair and recovery.
Why Long COVID Needs New Solutions
Long COVID often involves a “stuck” immune response, microvascular damage, chronic inflammation, and multi‑system fatigue that traditional medicine struggles to address. Many patients feel dismissed or are offered only piecemeal symptom management, leading them to seek more comprehensive, root‑cause approaches.
Dekabi’s Personalized, Holistic Approach
Dekabi Stem Cell Clinic in Seoul’s Gangnam district is presented as a model for personalized, systems-based care. Under Dr. Eun Young Baek, who brings more than 22 years of stem cell expertise and 34 years in medicine, the clinic customizes 1:1 protocols based on immune profiles, history, and symptom burden. Stem cell infusions are combined with energy medicine, detoxification, functional neurology, and anti‑aging/chronic disease management to address both Long COVID and coexisting conditions like diabetes or cardiovascular disease.
From Experimental to Evidence‑Based Hope
We see that global trials in Europe, Asia, and the U.S. are rapidly expanding the evidence base for MSCs in COVID‑related conditions. With regulatory approvals of stem cell therapies in related immune disorders and encouraging longitudinal data, regenerative medicine is moving from experimental to evidence‑based clinical practice. For patients, this translates into a potential path not only to symptom relief but to renewed energy, clearer cognition, better breathing, and a genuine “new beginning” after Long COVID
